Ethics Approval to Commence Clinical Trial in COVID-19
Filed with ASX · · 3 pages · English
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Share Purchase Plan Booklet
- Cynata announces $5.55m capital raising
- Cynata MSCs beneficial in preclinical ARDS study
- Cynata provides guidance on planned clinical trials
- Market Update & Additional A$618k R&D Tax Refund
Later from Cynata Therapeutics
- Cynata Successfully Completes Share Purchase Plan
- Block Trade Proceeds to Reduce Director Loans
- Ethics Approval & Expedited Pathway for Phase 3 OA Trial
- Cynata Announces Positive Results from GvHD Trial Follow-up
- Cynata Appoints Dr Geoff Brooke as Chairman
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics